Marker for the diagnosis of cancer

A method for providing a prognosis to a subject diagnosed with a primary tumor to develop metastases, in particular peritoneal carcinosis, said method comprising steps of:

• providing a sample of primary tumor tissue obtained from the subject;
• determining the level of expression of at least phosphoglycerate kinase 1 (PGK1) gene, or fragments thereof, to obtain a gene expression pattern for the sample;
• and based on the gene expression pattern obtained, providing a prognosis to the subject.

A diagnostic kit, comprising at least one substance for detection of the activity and/or expression of phosphoglycerate kinase 1 (PGK1) and/or β-catenin, either alone or in combination with the detection of CXCR4 and/or CXCL12, for the diagnosis or prognosis of peritoneal carcinoses and/or metastatic primary tumors.

A method for the preventive treatment of peritoneal carcinoses and/or metastatic primary tumors in a subject in need thereof, wherein the method comprises the step of administering to the subject at least a pharmaceutically effective amount of a substance inhibiting the activity and/or expression of phosphoglycerate kinase 1 (PGK1).

A pharmaceutical composition comprising a substance that inhibits the activity and/or expression of phosphoglycerate kinase 1 (PGK1) and at least one pharmaceutically acceptable carrier.